Company receives notice of the issuance of a U.S. patent covering the lead formulation, NRX-101, a glycine site NMDA antagonist in clinical trials to treat.
LONDON, Jan. 12, 2023 /PRNewswire/ The Psychedelic Drugs Market is anticipated to reach a valuation of USD 11.82 billion by 2029 from USD 4.87 billion in 2022, registering a CAGR of 13.49%
/PRNewswire/ The Psychedelic Drugs Market is anticipated to reach a valuation of USD 11.82 billion by 2029 from USD 4.87 billion in 2022, registering a CAGR.
Investegate announcements from Relief Therapeutics Holding SA, Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements
Relief Therapeutics Holding SA / Key word(s): Legal Matter Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements 20-Dec-2022 / 07:00 CET/CEST Release